768 related articles for article (PubMed ID: 34846524)
1. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.
Chen D; Chen H; Chi L; Fu M; Wang G; Wu Z; Xu S; Sun C; Xu X; Lin L; Cheng J; Jiang W; Dong X; Lu J; Zheng J; Chen G; Li G; Zhuo S; Yan J
JAMA Netw Open; 2021 Nov; 4(11):e2136388. PubMed ID: 34846524
[TBL] [Abstract][Full Text] [Related]
2. Pathomics Signature for Prognosis and Chemotherapy Benefits in Stage III Colon Cancer.
Jiang W; Wang H; Dong X; Yu X; Zhao Y; Chen D; Yan B; Cheng J; Zhuo S; Wang H; Yan J
JAMA Surg; 2024 May; 159(5):519-528. PubMed ID: 38416471
[TBL] [Abstract][Full Text] [Related]
3. Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer.
Jiang Y; Li T; Liang X; Hu Y; Huang L; Liao Z; Zhao L; Han Z; Zhu S; Wang M; Xu Y; Qi X; Liu H; Yang Y; Yu J; Liu W; Cai S; Li G
JAMA Surg; 2017 Jul; 152(7):e171087. PubMed ID: 28538950
[TBL] [Abstract][Full Text] [Related]
4. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer.
Yan H; Chen Y; Yang Z; Li Z; Che X; Xiao J; Liu Y; Qu X
Front Immunol; 2020; 11():621623. PubMed ID: 33613554
[TBL] [Abstract][Full Text] [Related]
5. Association of the Collagen Signature in the Tumor Microenvironment With Lymph Node Metastasis in Early Gastric Cancer.
Chen D; Chen G; Jiang W; Fu M; Liu W; Sui J; Xu S; Liu Z; Zheng X; Chi L; Lin D; Li K; Chen W; Zuo N; Lu J; Chen J; Li G; Zhuo S; Yan J
JAMA Surg; 2019 Mar; 154(3):e185249. PubMed ID: 30698615
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Clinicopathological Characteristics and Development of an Individualized Prognostic Model for Patients With Hepatoid Adenocarcinoma of the Stomach.
Lin JX; Wang ZK; Hong QQ; Zhang P; Zhang ZZ; He L; Wang Q; Shang L; Wang LJ; Sun YF; Li ZX; Liu JJ; Ding FH; Lin ED; Fu YA; Lin SM; Xie JW; Li P; Zheng CH; Huang CM
JAMA Netw Open; 2021 Oct; 4(10):e2128217. PubMed ID: 34609494
[TBL] [Abstract][Full Text] [Related]
7. Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit.
Jiang Y; Xie J; Han Z; Liu W; Xi S; Huang L; Huang W; Lin T; Zhao L; Hu Y; Yu J; Zhang Q; Li T; Cai S; Li G
Clin Cancer Res; 2018 Nov; 24(22):5574-5584. PubMed ID: 30042208
[No Abstract] [Full Text] [Related]
8. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study.
Jiang Y; Liang X; Han Z; Wang W; Xi S; Li T; Chen C; Yuan Q; Li N; Yu J; Xie Y; Xu Y; Zhou Z; Poultsides GA; Li G; Li R
Lancet Digit Health; 2021 Jun; 3(6):e371-e382. PubMed ID: 34045003
[TBL] [Abstract][Full Text] [Related]
9. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
10. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics-Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer.
Yu Y; Tan Y; Xie C; Hu Q; Ouyang J; Chen Y; Gu Y; Li A; Lu N; He Z; Yang Y; Chen K; Ma J; Li C; Ma M; Li X; Zhang R; Zhong H; Ou Q; Zhang Y; He Y; Li G; Wu Z; Su F; Song E; Yao H
JAMA Netw Open; 2020 Dec; 3(12):e2028086. PubMed ID: 33289845
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer: A Multicenter, Retrospective Study.
Jiang Y; Jin C; Yu H; Wu J; Chen C; Yuan Q; Huang W; Hu Y; Xu Y; Zhou Z; Fisher GA; Li G; Li R
Ann Surg; 2021 Dec; 274(6):e1153-e1161. PubMed ID: 31913871
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer.
Wang Y; Wang C; Xiao H; Niu C; Wu H; Jin H; Yao C; He H; Tian H; Han F; Li D; Han W; Xu J; Chen J; Cui J; Li W
Cancer Med; 2017 Jan; 6(1):45-53. PubMed ID: 27790867
[TBL] [Abstract][Full Text] [Related]
14. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
15. Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.
Cao Y; Liu H; Li H; Lin C; Li R; Wu S; Zhang H; He H; Zhang W; Xu J
JAMA Surg; 2017 Nov; 152(11):e173120. PubMed ID: 28903131
[TBL] [Abstract][Full Text] [Related]
16. [Clinical implications of Naples prognostic scores in patients with resectable Siewert type II-III adenocarcinoma of the esophagogastric junction].
Jin P; Ma G; Liu Y; Ke B; Liu HM; Liang H; Zhang RP
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jan; 27(1):54-62. PubMed ID: 38262901
[No Abstract] [Full Text] [Related]
17. Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study.
Lin JX; Lin JP; Weng Y; Lv CB; Chen JH; Zhan CY; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Zhou WX; Zhang XJ; Zheng CH; Cai LS; Ma YB; Huang CM
Ann Surg Oncol; 2022 Aug; 29(8):5022-5033. PubMed ID: 35294651
[TBL] [Abstract][Full Text] [Related]
18. Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer.
Karagkounis G; Squires MH; Melis M; Poultsides GA; Worhunsky D; Jin LX; Fields RC; Spolverato G; Pawlik TM; Votanopoulos KI; Levine EA; Schmidt C; Bloomston M; Cho CS; Weber S; Masi A; Berman R; Pachter HL; Staley CA; Newman E; Maithel SK; Hatzaras I
J Gastrointest Surg; 2017 Dec; 21(12):1984-1992. PubMed ID: 28963709
[TBL] [Abstract][Full Text] [Related]
19. Association of the Collagen Signature in the Tumor Microenvironment With Recurrence and Survival of Patients With T4N0M0 Colon Cancer.
Chen W; Dong S; Liu X; Wang G; Xu S; Lei S; Zhuo S; Yan J
Dis Colon Rectum; 2021 May; 64(5):563-575. PubMed ID: 33538520
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
